vs
Side-by-side financial comparison of ADMA BIOLOGICS, INC. (ADMA) and VIRTUS INVESTMENT PARTNERS, INC. (VRTS). Click either name above to swap in a different company.
VIRTUS INVESTMENT PARTNERS, INC. is the larger business by last-quarter revenue ($208.0M vs $139.2M, roughly 1.5× ADMA BIOLOGICS, INC.). ADMA BIOLOGICS, INC. runs the higher net margin — 35.5% vs 16.3%, a 19.2% gap on every dollar of revenue. On growth, ADMA BIOLOGICS, INC. posted the faster year-over-year revenue change (18.4% vs -10.9%). ADMA BIOLOGICS, INC. produced more free cash flow last quarter ($34.6M vs $-74.1M). Over the past eight quarters, ADMA BIOLOGICS, INC.'s revenue compounded faster (30.4% CAGR vs -3.2%).
ADMA Biologics Inc. is a biopharmaceutical enterprise focused on the research, development, manufacturing and commercialization of specialty plasma-derived immunoglobulin therapies. It primarily operates in the United States, catering to patients with primary immunodeficiency and other immune-related disorders, healthcare providers and medical institutions across its core immune health therapeutic segment.
VIRTUS INVESTMENT PARTNERS, INC.VRTSEarnings & Financial Report
Virtus Investment Partners, Inc. is an American company which operates as a multi-manager asset management business, comprising a number of individual affiliated managers, each having its own investment process and brand, and the services of unaffiliated sub advisers.
ADMA vs VRTS — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $139.2M | $208.0M |
| Net Profit | $49.4M | $33.9M |
| Gross Margin | 63.8% | — |
| Operating Margin | 45.1% | 19.1% |
| Net Margin | 35.5% | 16.3% |
| Revenue YoY | 18.4% | -10.9% |
| Net Profit YoY | -55.9% | -14.2% |
| EPS (diluted) | $0.20 | $5.15 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $139.2M | $208.0M | ||
| Q3 25 | $134.2M | $216.4M | ||
| Q2 25 | $122.0M | $210.5M | ||
| Q1 25 | $114.8M | $217.9M | ||
| Q4 24 | $117.5M | $233.5M | ||
| Q3 24 | $119.8M | $227.0M | ||
| Q2 24 | $107.2M | $224.4M | ||
| Q1 24 | $81.9M | $222.0M |
| Q4 25 | $49.4M | $33.9M | ||
| Q3 25 | $36.4M | $31.3M | ||
| Q2 25 | $34.2M | $42.7M | ||
| Q1 25 | $26.9M | $28.1M | ||
| Q4 24 | $111.9M | $39.5M | ||
| Q3 24 | $35.9M | $49.1M | ||
| Q2 24 | $32.1M | $26.0M | ||
| Q1 24 | $17.8M | $37.9M |
| Q4 25 | 63.8% | — | ||
| Q3 25 | 56.3% | — | ||
| Q2 25 | 55.1% | — | ||
| Q1 25 | 53.2% | — | ||
| Q4 24 | 53.9% | — | ||
| Q3 24 | 49.8% | — | ||
| Q2 24 | 53.6% | — | ||
| Q1 24 | 47.8% | — |
| Q4 25 | 45.1% | 19.1% | ||
| Q3 25 | 38.0% | 21.7% | ||
| Q2 25 | 35.1% | 21.5% | ||
| Q1 25 | 30.4% | 16.8% | ||
| Q4 24 | 32.6% | 21.7% | ||
| Q3 24 | 33.1% | 24.3% | ||
| Q2 24 | 36.6% | 19.7% | ||
| Q1 24 | 26.7% | 14.5% |
| Q4 25 | 35.5% | 16.3% | ||
| Q3 25 | 27.1% | 14.5% | ||
| Q2 25 | 28.1% | 20.3% | ||
| Q1 25 | 23.4% | 12.9% | ||
| Q4 24 | 95.2% | 16.9% | ||
| Q3 24 | 30.0% | 21.6% | ||
| Q2 24 | 29.9% | 11.6% | ||
| Q1 24 | 21.7% | 17.1% |
| Q4 25 | $0.20 | $5.15 | ||
| Q3 25 | $0.15 | $4.65 | ||
| Q2 25 | $0.14 | $6.12 | ||
| Q1 25 | $0.11 | $4.05 | ||
| Q4 24 | $0.45 | $4.65 | ||
| Q3 24 | $0.15 | $5.71 | ||
| Q2 24 | $0.13 | $2.43 | ||
| Q1 24 | $0.08 | $4.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $87.6M | — |
| Total DebtLower is stronger | $72.1M | $390.0M |
| Stockholders' EquityBook value | $477.3M | $934.0M |
| Total Assets | $624.2M | $4.3B |
| Debt / EquityLower = less leverage | 0.15× | 0.42× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $87.6M | — | ||
| Q3 25 | $61.4M | — | ||
| Q2 25 | $90.3M | — | ||
| Q1 25 | $71.6M | — | ||
| Q4 24 | $103.1M | — | ||
| Q3 24 | $86.7M | — | ||
| Q2 24 | $88.2M | — | ||
| Q1 24 | $45.3M | — |
| Q4 25 | $72.1M | $390.0M | ||
| Q3 25 | $72.4M | $390.6M | ||
| Q2 25 | — | $231.3M | ||
| Q1 25 | — | $231.7M | ||
| Q4 24 | $72.3M | $232.1M | ||
| Q3 24 | — | $237.5M | ||
| Q2 24 | — | $247.6M | ||
| Q1 24 | — | $253.0M |
| Q4 25 | $477.3M | $934.0M | ||
| Q3 25 | $431.2M | $918.7M | ||
| Q2 25 | $398.3M | $896.4M | ||
| Q1 25 | $373.4M | $893.7M | ||
| Q4 24 | $349.0M | $897.5M | ||
| Q3 24 | $231.9M | $889.0M | ||
| Q2 24 | $188.3M | $868.7M | ||
| Q1 24 | $153.7M | $871.7M |
| Q4 25 | $624.2M | $4.3B | ||
| Q3 25 | $568.7M | $3.9B | ||
| Q2 25 | $558.4M | $3.7B | ||
| Q1 25 | $510.6M | $3.7B | ||
| Q4 24 | $488.7M | $4.0B | ||
| Q3 24 | $390.6M | $3.6B | ||
| Q2 24 | $376.4M | $3.6B | ||
| Q1 24 | $350.9M | $3.5B |
| Q4 25 | 0.15× | 0.42× | ||
| Q3 25 | 0.17× | 0.43× | ||
| Q2 25 | — | 0.26× | ||
| Q1 25 | — | 0.26× | ||
| Q4 24 | 0.21× | 0.26× | ||
| Q3 24 | — | 0.27× | ||
| Q2 24 | — | 0.29× | ||
| Q1 24 | — | 0.29× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $35.6M | $-67.2M |
| Free Cash FlowOCF − Capex | $34.6M | $-74.1M |
| FCF MarginFCF / Revenue | 24.8% | -35.6% |
| Capex IntensityCapex / Revenue | 0.8% | 3.3% |
| Cash ConversionOCF / Net Profit | 0.72× | -1.99× |
| TTM Free Cash FlowTrailing 4 quarters | $27.8M | $100.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $35.6M | $-67.2M | ||
| Q3 25 | $13.3M | $108.3M | ||
| Q2 25 | $21.1M | $75.8M | ||
| Q1 25 | $-19.7M | $-3.8M | ||
| Q4 24 | $50.2M | $1.8M | ||
| Q3 24 | $25.0M | $69.1M | ||
| Q2 24 | $45.6M | $70.0M | ||
| Q1 24 | $-2.2M | $-34.5M |
| Q4 25 | $34.6M | $-74.1M | ||
| Q3 25 | $-1.1M | $106.9M | ||
| Q2 25 | $18.7M | $74.2M | ||
| Q1 25 | $-24.4M | $-6.8M | ||
| Q4 24 | $47.5M | $-3.8M | ||
| Q3 24 | $24.0M | $68.7M | ||
| Q2 24 | $43.6M | $68.6M | ||
| Q1 24 | $-4.6M | $-36.5M |
| Q4 25 | 24.8% | -35.6% | ||
| Q3 25 | -0.8% | 49.4% | ||
| Q2 25 | 15.3% | 35.2% | ||
| Q1 25 | -21.2% | -3.1% | ||
| Q4 24 | 40.4% | -1.6% | ||
| Q3 24 | 20.0% | 30.3% | ||
| Q2 24 | 40.7% | 30.6% | ||
| Q1 24 | -5.6% | -16.4% |
| Q4 25 | 0.8% | 3.3% | ||
| Q3 25 | 10.7% | 0.7% | ||
| Q2 25 | 2.0% | 0.7% | ||
| Q1 25 | 4.1% | 1.4% | ||
| Q4 24 | 2.3% | 2.4% | ||
| Q3 24 | 0.9% | 0.2% | ||
| Q2 24 | 1.9% | 0.6% | ||
| Q1 24 | 2.9% | 0.9% |
| Q4 25 | 0.72× | -1.99× | ||
| Q3 25 | 0.36× | 3.45× | ||
| Q2 25 | 0.62× | 1.77× | ||
| Q1 25 | -0.73× | -0.13× | ||
| Q4 24 | 0.45× | 0.04× | ||
| Q3 24 | 0.70× | 1.41× | ||
| Q2 24 | 1.42× | 2.69× | ||
| Q1 24 | -0.12× | -0.91× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ADMA
| ADMA Bio Manufacturing Segment | $123.1M | 88% |
| Other | $16.0M | 12% |
VRTS
| Open End Funds | $68.9M | 33% |
| Retail Separate Accounts | $51.3M | 25% |
| Institutional Accounts | $39.6M | 19% |
| Administration And Shareholder Service Fees | $18.4M | 9% |
| Closed End Funds | $15.9M | 8% |
| Distribution And Service Fees | $12.3M | 6% |
